Share this article
Share this article
ResearchAndMarkets.com s offering.
This first edition report
At-Home Testing: COVID-19 Trends and Future Potential provides an overview of trends and developments in the home testing industry for the pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This report covers trends that have occurred since the pandemic was declared in 2020 to the recent present - March 31, 2021.
For the purpose of this report, the analyst concludes that the accepted definition of a home or self-test is one whereby the individual takes the sample, performs the test and then interprets the test result either alone or with the aid of an online consultation service. As of the time of publication in Spring 2021, the major market for COVID-19 self-tests is the United States, therefore the discussion presented in the report focuses on that geography.
Isra Miraj dan Urgensi Sanad, Mata Rantai Keilmuan republika.co.id - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from republika.co.id Daily Mail and Mail on Sunday newspapers.
新年焕新, ｉ绵阳 APP春节服务专区上线啦!_绵阳新闻网 myrb.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from myrb.net Daily Mail and Mail on Sunday newspapers.
(Pixabay)
Welcome to this week s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word or the bad from your shop to Fraiser Kansteiner, and we will feature it here at the end of each week.
Another GSK vaccine exec jumps ship for biotech CEO role
GlaxoSmithKline
Amir Reichman is stepping down.
Reichman is leaving his post as head of global vaccines engineering core technology at GSK to eventually head up operations at BiondVax Pharmaceuticals. Reichman will split duties with BiondVax’s founder and CEO Ron Babecoff until March 2 as he wraps his time at GSK. Reichman joined GSK in 2015 as part of a multibillion-dollar deal that saw GSK trade off its oncology assets for Novartis’ vaccines unit. Reichman held various positions at Novartis in its vaccine supply chain unit before becoming director of GSK’s global vaccines supply chain and then head of global vaccines engineering